JP Morgan Maintains Overweight on Zymeworks, Raises Price Target to $33
Benzinga Newsdesk 1 month ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $31 to $33.
JP Morgan analyst Brian Cheng maintains Zymeworks (NASDAQ:ZYME) with a Overweight and raises the price target from $31 to $33.